AGC to manufacture adjuvant for Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus vaccine candidate, NVX-CoV2373.

AGC will manufacture Matrix-M, the adjuvant component of the vaccine candidate that helps enhance the immune response and stimulate high levels of neutralizing antibodies. The vaccine candidate is a prefusion protein made using Novavax's proprietary nanoparticle technology.

AGC plans to optimize process development for rapid scale-up of Matrix-M to increase Novavax's capacity to deliver doses of the vaccine this year. Phase I clinical trial results for NVX-CoV2373 are expected in July.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: